Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tegaserod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 5/20 | 0.70 |
| ▸ | HTR2C | P28335 | 5/20 | 0.70 |
| ▸ | HTR1D | P28221 | 3/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.70 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.70 |
| ▸ | DRD2 | P14416 | 2/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.70 |
| ▸ | DRD4 | P21917 | 2/20 | 0.70 |
| ▸ | HTR2A | P28223 | 2/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.70 |
| ▸ | DRD3 | P35462 | 2/20 | 0.70 |
| ▸ | HTR2B | P41595 | 2/20 | 0.70 |
| ▸ | HTR3A | P46098 | 2/20 | 0.70 |
| ▸ | HTR5A | P47898 | 2/20 | 0.70 |
| ▸ | HTR6 | P50406 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | DRD5 | P21918 | 1/20 | 0.70 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tegaserod SCHEMBL20362149 | 1.00 | HTR1A (0.70) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL1042179 | 1.00 | HTR1A (0.70) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL3893820 | 1.00 | HTR1A (0.70) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL27215 | 1.00 | HTR1A (0.70) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL4643931 | 0.99 | HTR1A (0.69) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL3229259 | 0.95 | HTR1A (0.63) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL3892146 | 0.95 | HTR1A (0.63) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL4637068 | 0.95 | HTR1A (0.62) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL4636808 | 0.95 | HTR1A (0.62) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL16464 | 0.94 | HTR1A (0.67) | HTR1AHTR2CHTR1DADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007119109-A2 | PROCESSES FOR PREPARING TEGASEROD MALEATE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDICHEM, S.A. (US) | 2007-10-25 | — | — | WO | claimed |
| US-20250375419-A1 | NOVEL RAS INHIBITORS | KHR Biotec GmbH (DE) | 2025-12-11 | — | — | US | disclosed |
| EP-4577305-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | 1/1THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4536635-A1 | NOVEL RAS INHIBITORS | KHR Biotec GmbH (DE) | 2025-04-16 | — | — | EP | disclosed |
| WO-2024044355-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | 1/1THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023242102-A1 | NOVEL RAS INHIBITORS | KHR Biotec GmbH (DE) | 2023-12-21 | — | — | WO | disclosed |
| US-20230121608-A1 | Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety- Like Behavior | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-04-20 | — | — | US | disclosed |
| CN-115916174-A | Compositions and methods for preventing stress-induced phobia, depression-like, and anxiety-like behaviors | 纽约市哥伦比亚大学理事会 | 2023-04-04 | — | — | CN | disclosed |
| EP-4132496-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION OF STRESS-INDUCED FEAR, DEPRESSIVE-LIKE AND ANXIETY- LIKE BEHAVIOR | The Trustees of Columbia University in the City of New York (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3952852-A1 | PROPHYLACTIC EFFICACY OF SEROTONIN 4 RECEPTOR AGONISTS AGAINST STRESS | The Trustees of Columbia University in the City of New York (US) | 2022-02-16 | — | — | EP | disclosed |
| US-8436021-B2 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2013-05-07 | — | — | US | disclosed |
| US-20090124592-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY | CENTRE NAT DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-05-14 | — | — | US | disclosed |
| WO-2007119109-A3 | PROCESSES FOR PREPARING TEGASEROD MALEATE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDICHEM SA (ES) | 2008-06-12 | — | — | WO | disclosed |
| EP-1893195-A2 | POLYMORPHIC FORMS OF TEGASEROD MALEATE | Teva Pharmaceutical Industries Ltd (IL) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007119109-A2 | PROCESSES FOR PREPARING TEGASEROD MALEATE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDICHEM, S.A. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007119109-A2 | PROCESSES FOR PREPARING TEGASEROD MALEATE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDICHEM, S.A. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070112057-A1 | Polymorphic forms of tegaserod maleate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
| US-20070112056-A1 | Stable modifications of tegaserod hydrogen maleate | NOVARTIS AG (CH) | 2007-05-17 | — | — | US | disclosed |
| WO-2007002314-A2 | POLYMORPHIC FORMS OF TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-01-04 | — | — | WO | disclosed |
| US-20060116341-A1 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, AN ORGANIZATION OF FRANCE (FR) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112057-A1 | Polymorphic forms of tegaserod maleate | UGT1A3, CYP3A43, MLNR | HTR4 302/4885HTR1A 128/4885HTR2C 893/4885 |
| US-20250375419-A1 | NOVEL RAS INHIBITORS | KRAS, NRAS, HRAS | HTR4 4756/4885HTR1A 3883/4885HTR2C 4679/4885 |
| US-20070112056-A1 | Stable modifications of tegaserod hydrogen maleate | HRH2, HRH4, HRH1 | HTR4 12/4885HTR1A 23/4885HTR2C 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.